Citius Pharmaceuticals (CTXR) vs Karyopharm Therapeutics (KPTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Citius Pharmaceuticals (CTXR) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 62.0% versus a loss of 89.8%. Over five years, CTXR leads with a -99.1% price change compared with -99.3% for KPTI. Karyopharm Therapeutics is the larger company by market cap ($13.6 million vs $13.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTXR | KPTI |
|---|---|---|
| Share price | $0.4887 | $0.60 |
| Market cap | $13.42M | $13.61M |
| 1-day change | -2.47% | -6.98% |
| YTD return | -37.10% | -91.85% |
| 1-year return | -61.97% | -89.83% |
| 5-year return | -99.06% | -99.28% |
| EPS (TTM) | $-1.75 | $-14.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.19 | $10.99 |
| 52-week low | $0.469 | $0.60 |
| Distance from 52-week high | -77.68% | -94.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +718.50% | +1108.33% |
| Average volume | 527.79K | 1.71M |
| Shares outstanding | 27.45M | 22.68M |
| Employees | 23 | 228 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CTXR has outperformed KPTI by 27.9 percentage points over the past year.
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
CTXR vs KPTI FAQ
Which is bigger, Citius Pharmaceuticals or Karyopharm Therapeutics?
Karyopharm Therapeutics (KPTI) is larger, with a market capitalization of $13.61M compared with $13.42M for Citius Pharmaceuticals (CTXR).
Which stock has performed better over the past year, CTXR or KPTI?
CTXR returned -61.97% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Citius Pharmaceuticals and Karyopharm Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.